Portfolio company
Azalea Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops in vivo genome editing therapies to engineer T cells directly inside the body for patients with cancer and autoimmune diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Alia Therapeutics
The company develops gene editing medicines for patients with genetic diseases.
Umoja Biopharma
This biotechnology company develops in vivo cell therapies to treat oncology and autoimmunity patients by generating chimeric antigen receptor T cells inside the body.
Autolus Therapeutics
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.
Modulari-T Biosciences
This company develops modular immune receptors and delivery vehicles to create cell and gene therapies for patients with cancer and autoimmune diseases.
Egle Therapeutics
This biotechnology company develops precision medicines that modulate regulatory T cells to treat patients with autoimmune diseases and cancer.
EdiTy Therapeutics
This company develops immune cell delivery platforms to transport therapeutic proteins into diseased cells for patients with cancer and genetic disorders.
Stylus Medicine
This biotechnology company develops in vivo genetic medicines using engineered recombinases and lipid nanoparticles for patients with cancer, autoimmune and genetic diseases.
ArsenalBio
The company develops programmable T cell therapies for patients with solid tumours and autoimmune diseases.